Reporting to the Executive Director of Corporate Accounts, the Corporate Account Director (CAD) will be responsible for securing access and reimbursement of AVEO’s lead product across all assigned payor accounts (national, regional and government).
The CAD will serve as the lead point of contact for all AVEO business related to assigned payor accounts and managing business activities within those accounts. They will develop, maintain, and execute account plans that contribute to the defined business goals and objectives of the organization. Most critically, the CAD is responsible for securing and protecting optimal payor access to AVEO’s lead product, while developing relationships that align to the business needs of the account and AVEO Oncology.
Lastly, the CAD is responsible for working with various field and home office teams to ensure the appropriate level of cross-functional support for their assigned accounts. They will develop and execute pull-through plans by strategically utilizing corporate resources, while providing AVEO with evolving market and account intelligence.
- Lead the development of account specific plans that build positive business relationships within assigned payor accounts to ensure optimal product access
- Effectively communicate payor specific rules and policies to the field sales organization in order to efficiently develop and execute pull through plans
- Compliantly engage Medical Affairs resources to support critical AVEO business initiatives across assigned accounts.
- Develop and maintain effective working relationships with Key C-Suite and decision makers within an account (CEO, CFO, CMO, Dir. Of Pharmacy, Dir. of Quality, Industry Relations, etc.)
- Seek out opportunities for synergy and partnership to achieve mutually beneficial goals for both AVEO and the accounts through active and transparent collaboration
- Understand the field access landscape and engage in key local, national, and international health care issues/strategies, account issues/trends, and best practices to establish credibility beyond product and disease state
- Review and analyze product performance at the account level and communicate account performance broadly with key internal stakeholders
- Represent AVEO Oncology at key national industry conferences and congress (PCMA, Asembia, AMCP, AHIP, etc.)
- Facilitate and manage the engagement of executive-to-executive meetings
- Conduct key accounts situational assessments through market research, landscape analysis, direct customer interactions, published reports, policy updates and/or account analytics to proactively identify potential market access threats or opportunities
- Ensure compliance with corporate policies and procedures, along with US healthcare laws and regulations
- Bachelor’s Degree required / MBA preferred
- 10+ years of working in the pharma/biotech space, with at least 5 years in payor account management
- Established relationships with national and regional payors
- Outstanding interpersonal and communication skills with the established ability to effectively work with diverse audiences and influence cross-functionally
- Strong negotiation skills
- Oral oncolytic experience preferred
- Strong analytical skills with the proven ability to effectively analyze data to determine trends and inform strategy
- Strong oral and written presentation skills and executive presence.
- Ability to influence and lead across functions; operate in a matrix environment.
- This position requires 40% domestic travel
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma and other cancers. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and at progressing its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome). Tivozanib (FOTIVDA®) is approved by the European Commission for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland.